Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Operation Wildfire

This article was originally published in The Tan Sheet

Executive Summary

Agents seized "209 pounds of methamphetamines, 201,035 tablets of pseudoephedrine, 158 kilograms of pseudoephedrine powder and 224,860 tablets of ephedrine" during "Operation Wildfire," the "largest nationally coordinated law enforcement initiative" to date, DEA announces Aug. 30. Wildfire was "designed to target all levels of the methamphetamine manufacturing and distribution chain" in the U.S. and involved authorities in more than 200 cities. Most of the pseudoephedrine was bought from "mom and pop" stores and pharmacies, and represented a combination of dosage forms, DEA said. The initiative closely follows the White House's announcement of a meth strategy that supports national pseudoephedrine purchase limits, but not behind-the-counter sale (1"The Tan Sheet," Aug. 22, 2005, p. 4)...

You may also be interested in...



White House Meth Bill Plan Would Not Put Pseudoephedrine Behind Counters

The Bush Administration supports federal meth legislation that would apply significantly fewer restrictions on pseudoephedrine than the pending Talent/Feinstein senate bill

QUOTED. 13 December 2019. Todd Garner

ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs.  See what the CFO said about it here.

Sarepta Scores Another Remarkable Approval With Vyondys 53 For Duchenne

Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.

Topics

UsernamePublicRestriction

Register

PS098604

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel